IBDEI1XF ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30774,0)
 ;;=R33.9^^123^1585^24
 ;;^UTILITY(U,$J,358.3,30774,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30774,1,3,0)
 ;;=3^Urinary Retention,Unspec
 ;;^UTILITY(U,$J,358.3,30774,1,4,0)
 ;;=4^R33.9
 ;;^UTILITY(U,$J,358.3,30774,2)
 ;;=^5019332
 ;;^UTILITY(U,$J,358.3,30775,0)
 ;;=D51.8^^123^1586^2
 ;;^UTILITY(U,$J,358.3,30775,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30775,1,3,0)
 ;;=3^Anemia,Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,30775,1,4,0)
 ;;=4^D51.8
 ;;^UTILITY(U,$J,358.3,30775,2)
 ;;=^5002288
 ;;^UTILITY(U,$J,358.3,30776,0)
 ;;=D52.9^^123^1586^1
 ;;^UTILITY(U,$J,358.3,30776,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30776,1,3,0)
 ;;=3^Anemia,Folate Deficiency
 ;;^UTILITY(U,$J,358.3,30776,1,4,0)
 ;;=4^D52.9
 ;;^UTILITY(U,$J,358.3,30776,2)
 ;;=^5002293
 ;;^UTILITY(U,$J,358.3,30777,0)
 ;;=I10.^^123^1587^12
 ;;^UTILITY(U,$J,358.3,30777,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30777,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,30777,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,30777,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,30778,0)
 ;;=I15.0^^123^1587^13
 ;;^UTILITY(U,$J,358.3,30778,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30778,1,3,0)
 ;;=3^Hypertension,Renovascular
 ;;^UTILITY(U,$J,358.3,30778,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,30778,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,30779,0)
 ;;=I13.11^^123^1587^8
 ;;^UTILITY(U,$J,358.3,30779,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30779,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,30779,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,30779,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,30780,0)
 ;;=I13.2^^123^1587^7
 ;;^UTILITY(U,$J,358.3,30780,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30780,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,30780,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,30780,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,30781,0)
 ;;=I70.1^^123^1587^3
 ;;^UTILITY(U,$J,358.3,30781,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30781,1,3,0)
 ;;=3^Atherosclerosis of Renal Artery
 ;;^UTILITY(U,$J,358.3,30781,1,4,0)
 ;;=4^I70.1
 ;;^UTILITY(U,$J,358.3,30781,2)
 ;;=^269760
 ;;^UTILITY(U,$J,358.3,30782,0)
 ;;=I77.3^^123^1587^2
 ;;^UTILITY(U,$J,358.3,30782,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30782,1,3,0)
 ;;=3^Arterial Fibromuscular Dysplasia
 ;;^UTILITY(U,$J,358.3,30782,1,4,0)
 ;;=4^I77.3
 ;;^UTILITY(U,$J,358.3,30782,2)
 ;;=^5007812
 ;;^UTILITY(U,$J,358.3,30783,0)
 ;;=E26.02^^123^1587^5
 ;;^UTILITY(U,$J,358.3,30783,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30783,1,3,0)
 ;;=3^Glucocorticoid-Remediable Aldosteronism
 ;;^UTILITY(U,$J,358.3,30783,1,4,0)
 ;;=4^E26.02
 ;;^UTILITY(U,$J,358.3,30783,2)
 ;;=^329904
 ;;^UTILITY(U,$J,358.3,30784,0)
 ;;=I12.9^^123^1587^14
 ;;^UTILITY(U,$J,358.3,30784,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30784,1,3,0)
 ;;=3^Hypertensive CKD Stage 1-4
 ;;^UTILITY(U,$J,358.3,30784,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,30784,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,30785,0)
 ;;=I12.0^^123^1587^15
 ;;^UTILITY(U,$J,358.3,30785,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30785,1,3,0)
 ;;=3^Hypertensive CKD Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,30785,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,30785,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,30786,0)
 ;;=I13.0^^123^1587^6
 ;;^UTILITY(U,$J,358.3,30786,1,0)
 ;;=^358.31IA^4^2
